Pierre Gascon

Dr. Pierre Gascon

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
PGPierre Gascon
Pierre Gascon
ABAntoine Briantais
Antoine Briantais
EBEmmanuelle Bertrand
Emmanuelle Bertrand
PRPrithvi Ramtohul
Prithvi Ramtohul
ACAlban Comet
Alban Comet
DDDanièle Denis
Danièle Denis
A 53-year-old man presented with acute loss of vision, negative scotoma and dyschromatopsia in his left eye. He reported contact with people with severe respiratory syndrome - coronavirus-2 (SARS-C...

Verified
Journal Article
Open access
PDF file
PAPatricia Ancel
Patricia Ancel
JMJean Charles Martin
Jean Charles Martin
EDElisa Doukbi
Elisa Doukbi
MHMarie Houssays
Marie Houssays
PGPierre Gascon
Pierre Gascon
BGBénédicte GABORIT
Bénédicte GABORIT
Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus (DM) which is the main cause of vision loss in the working-age population. Currently known risk factors such as age, disease duration, and hemoglobin A1c lack sufficient efficiency to distinguish patients with early stages of DR. A total of 194 plasma samples were collected from patients with type 2 DM and DR (moderate to proliferative (PDR) or control (no or mild DR) matched for age, gender, diabetes duration, HbA1c, and hypertension. Untargeted lipidomic and metabolomic approaches were performed. Partial-least square methods were used to analyze the datasets. Levels of 69 metabolites and 85 lipid species were found to be significantly different in the plasma of DR patients versus controls. Metabolite set enrichment analysis indicated that pathways such as metabolism of branched-chain amino acids (methylglutaryl carnitine p = 0.004), the kynurenine pathway (tryptophan p < 0.001), and microbiota metabolism (p-Cresol sulfate p = 0.004) were among the most enriched deregulated pathways in the DR group. Moreover, Glucose-6-phosphate (p = 0.001) and N-methyl-glutamate (p < 0.001) were upregulated in DR. Subgroup analyses identified a specific signature associated with PDR, macular oedema, and DR associated with chronic kidney disease. Phosphatidylcholines (PCs) were dysregulated, with an increase of alkyl-PCs (PC O-42:5 p < 0.001) in DR, while non-ether PCs (PC 14:0–16:1, p < 0.001; PC 18:2–14:0, p < 0.001) were decreased in the DR group. Through an unbiased multiomics approach, we identified metabolites and lipid species that interestingly discriminate patients with or without DR. These features could be a research basis to identify new potential plasma biomarkers to promote 3P medicine.

8 June 2020 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
ACAlban Comet
Alban Comet
PGPierre Gascon
Pierre Gascon
PRPrithvi Ramtohul
Prithvi Ramtohul
BDBenjamin Donnadieu
Benjamin Donnadieu
DDDanièle Denis
Danièle Denis
FMFREDERIC MATONTI
FREDERIC MATONTI
Purpose: To compare the efficacy of intravitreal injections (IVI) of ranibizumab (Lucentis®, Novartis, Basel, Switzerland; RAN), aflibercept (Eylea®, Bayer, Leverkusen, Germany; AFL) and dexamethasone implant (Ozurdex®, Allergan, Irvine, California; DXI) in the treatment of naive diabetic macular oedema (DME) during a 12-month follow-up, in real life. Methods: Nineteen eyes treated with RAN, 20 with AFL and 21 with DXI were analysed from inclusion up to 12 months (M12) with intermediate analysis at M6. Best corrected visual acuity (BCVA), fundus and central retinal thickness (CRT) using spectral-domain optical coherence tomography (SD-OCT; Spectralis/HRA, Heidelberg Engineering, Germany) were performed at inclusion, M3, M6 and M12. Results: BCVA improved until 67.9 letters ±13.3 SD (+5.5 letters) at M6 and 69.6 letters ±12 SD (+7.2 letters) at 12 months for RAN group ( p = 0.036). For the AFL group it improved until 63.6 letters ±15.2 SD (+6.6 letters) at M6 and 67.5 letters ±12.2 SD (+8.5 letters) at 12 months ( p = 0.014). Lastly DXI group improved by 66.9 letters ±15.1 SD (+7.9 letters) at M6 and 68.4 letters ±11.2 SD (+9.4 letters) at 12 months ( p = 0.0023). CRT decreased by 124.4 µm at M6 and 99.3 µm at M12 in RAN group, 144.3 µm and 101.5 µm in AFL group and finally 95.6 µm and 162.7 µm in DXI group. Conclusion: In summary, these three drugs provide an efficient treatment option with an acceptable benefit-risk ratio for the treatment of naive patients with DME, whether on BCVA or CRT on the first year of treatment.

25 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FMFREDERIC MATONTI
FREDERIC MATONTI
JKJean-François Korobelnik
Jean-François Korobelnik
CDCorinne Dot
Corinne Dot
VGVincent Gualino
Vincent Gualino
VSVincent Soler
Vincent Soler
Laurent KodjikianLaurent Kodjikian
Laurent Kodjikian
Intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) have become the standard of care for age-related macular degeneration (AMD). Although most pivotal trials have used monthly injections, alternative strategies that enable the injections to be administered on a more flexible schedule, including pro re nata (PRN) and treat-and-extend (T&E) regimens, are being applied more frequently. This review sought to provide further scientific evidence about the visual outcomes and treatment burden among the currently available anti-VEGF agents and regimens, including aflibercept, ranibizumab, abicipar and brolucizumab. To this end, a systematic review of published randomized studies was conducted from the MEDLINE and EMBASE databases and the Cochrane library, and a meta-analysis was applied to the obtained data using single-means modeling to compare the efficacy and maintenance among the different available treatments and regimens at Years 1 and 2. Quality analysis identified the best-informed data for modeling purposes. Overall, 47 relevant publications were retrieved for the analysis. Superior efficacy, meaning that there were observed improvements in visual acuity (VA) and central retinal thickness (CRT), occurred with monthly versus PRN regimens, yet a higher IVI number was also observed. Conversely, the T&E regimens displayed similar efficacy to the monthly regimens, but with a reduced IVI number. Aflibercept T&E exhibited similar efficacy to ranibizumab T&E, but with significantly lower IVI numbers at both Year 1 (p < 0.0001) and Year 2 (p = 0.0011). Though all of the regimens resulted in maintained efficacy between Years 1 and 2, the required IVI number varied. The retrieved data did not enable other regimens or newer anti-VEGF agents such as brolucizumab to be compared. In conclusion, the T&E regimens were shown to be the most efficient, optimizing durable effectiveness whilst minimizing the IVI number in newly diagnosed exudative AMD, with aflibercept requiring the lowest IVI number.

10 October 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
KMKevin Mairot
Kevin Mairot
PGPierre Gascon
Pierre Gascon
NSNatacha Stolowy
Natacha Stolowy
ACAlban Comet
Alban Comet
RARuben Attia
Ruben Attia
TDThierry David
Thierry David

26 May 2025 in Ophthalmology Retina
Verified
Journal Article
Closed access
PRPrithvi Ramtohul
Prithvi Ramtohul
MCMaria Vittoria Cicinelli
Maria Vittoria Cicinelli
FCFred Chen
Fred Chen
DODaniel J. Oh
Daniel J. Oh
BFBenjamin D. Freilich
Benjamin D. Freilich
KFK. Bailey Freund
K. Bailey Freund